Stroke · 2014 · 65 citations · 29 references
MedicineInternal MedicineHemostasisOutcomes ResearchVascular SurgeryAcute Ischemic StrokeAcute Stroke CareAcute Stroke ManagementCerebrovascular DiseaseStrokeThrombosisAcute Ischemic Stroke ThrombolysisAcute Ischemic Stroke TreatmentBleedingCox RegressionIntravenous Tissue Plasminogen ActivatorPlasminogen ActivatorsPropensity Score AdjustmentThrombolysis In Ischemic Stroke
BACKGROUND AND PURPOSE: Data on long-term outcome after intravenous tissue-type plasminogen activator (tPA) in ischemic stroke are limited. We examined the risk of long-term mortality, recurrent ischemic stroke, and major bleeding, including intracranial and gastrointestinal bleeding, in intravenous tPA-treated patients when compared with intravenous tPA eligible but nontreated patients with ischemic stroke. METHODS: We conducted a register-based nationwide propensity score-matched follow-up study among patients with ischemic stroke in Denmark (2004-2011). Cox regression analysis was used to compute adjusted hazard ratios for all outcomes. RESULTS: Among 4292 ischemic strokes (2146 intravenous tPA-treated and 2146 propensity score-matched nonintravenous tPA-treated patients), with a follow-up for a median of 1.4 years, treatment with intravenous tPA was associated with a lower risk of long-term mortality (adjusted hazard ratio, 0.66; 95% confidence interval, 0.49-0.88). The long-term risk of recurrent ischemic stroke (adjusted hazard ratio, 1.05; 95% confidence interval, 0.68-1.64) and major bleeding (adjusted hazard ratio, 0.59; 95% confidence interval, 0.24-1.47) did not differ significantly between the intravenous tPA-treated and nontreated patients. CONCLUSIONS: Treatment with intravenous tPA in patients with ischemic stroke was associated with improved long-term survival.
29
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Werner Hacke, Markku Kaste, Erich Bluhmki et al. · New England Journal of Medicine · 2008 · 6.6K citations · Full text